Patrik Jeanmonod - Feb 28, 2022 Form 4 Insider Report for Cytek Biosciences, Inc. (CTKB)

Role
Chief Financial Officer
Signature
/s/ Valerie Barnett, Attorney-in-Fact for Patrik Jeanmonod
Stock symbol
CTKB
Transactions as of
Feb 28, 2022
Transactions value $
$0
Form type
4
Date filed
3/2/2022, 04:54 PM
Previous filing
Jul 22, 2021
Next filing
May 20, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CTKB Stock Option (Right to Buy) Award $0 +42.3K $0.00 42.3K Feb 28, 2022 Common Stock 42.3K $13.64 Direct F1
transaction CTKB Restricted Stock Units Award $0 +28K $0.00 28K Feb 28, 2022 Common Stock 28K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/48th of the shares subject to the option vest monthly over four years from the vesting commencement date of January 1, 2022. The option becomes fully vested on January 1, 2026.
F2 Each Restricted Stock Unit (the "RSU Award") represents a contingent right to receive one share of the Issuer's common stock.
F3 The shares subject to the RSU Award shall vest quarterly over four years, with 4/48th of the total shares underlying the RSU Award vesting on May 18, 2022 and 3/48th of the total shares underlying the RSU Award vesting each subsequent quarter thereafter on August 18, November 18, February 18 and May 18.